What new antidiabetic drugs can do in present clinical practice

Česká verzia

Authors: Ján Murín
Authors place of work: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in the journal: Diab Obez 2021; 21(41): 51-54
Category: News

Zdroje

Murín J. Potrebujeme kardio-metabolických špecialistov? Diab Obez 2020; 20(40): 123–124.
[NCD Risk Factor Collaboration (NCD-RisC)]. Worldwide trends in body-mass index, underweight, overweight and obesity from 1975 to 2016: a pooled analysis of 2 416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017; 390(10113): 2627–2642. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)32129–3>.
Guariguata L, Whiting DR, Hambleton I et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103(2): 137–149. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2013.11.002>.
Booth GL, Kapral MK, Fung K et al. Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet 2006; 368(9529): 29–36. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(06)68967–8>.
Beckman JA, Paneni F, Cosentino F et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013; 34(31): 2444–2452. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht142>.
Low Wang CC, Hess CN, Hiatt WR et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation 2016; 133(24): 2459–2502. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022194>.
Gregg EW. Li Y, Wang J et al. Changes in diabetes-related complications in the United States. 1990–2010. N Engl J Med 2014; 370(16): 1514–1523. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1310799>.
Kivimäki M, Kuosma E, Ferrie JE et al. Overweight, obesity and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Hearth. 2017; 2(6): e277-e285. Dostupné z DOI: <http://dx.doi.org/10.1016/S2468–2667(17)30074–9>.
Tsioufis C. Andrikou E. Thomopoulos C et al. Oral glucose-lowering drugs and cardiovascular outcomes: from the negative RECORD and ACCORD to neutral TECOS and promising EMPA-REG. Curr Vasc Pharmacol 2017; 15(5): 457–468. Dostupné z DOI: <http://dx.doi.org/10.2174/1570161114666161208150642>.
Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
Neal B, Perkovic V, Mahaffey KW et al. CANVAS program collaborative group. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2. diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
[American Diabetes Association]. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 2018; 41(Suppl 1): S73-S85. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18-S008>.
Wiviott SD, Raz I, Bonaca MP et al. DECLARE-TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.
Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166): 31–39. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32590-X>.
Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72(15): 1845–1855. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2018.06.040>.
Andrikou E, Tsioufis C, Andrikou I et al. GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol 2019; 60(6): 347–351. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hjc.2018.11.008>.
Piepoli MF, Hoes AW, Agewall S et al. [ESC Scientific Document Group]. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>.
Manam R, Baum SJ. The Role of a Preventive Cardiologist in Managing the Diabetic Patient. Expert Analysis. Dostupné z WWW: <https://www.acc.org/latest-in-cardiology/articles/2018/03/15/11/00/the-role-of-a-preventive-cardiologist-in-managing-the-diabetic-patient#:~:text=Preventive%20cardiologists%20should%2C%20however%2C%20manage,managed%20by%20the%20preventive%20cardiologist>.
McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.
Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.
Heerspink HJ, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.